Haplomics, Inc. is developing a genetic cure for hemophilia using state-of-the-art, gene editing techniques, specifically using CRISPR/Cas9 mediation techniques. Haplomics is following a four-step research and development program to personalize the genetic repair of all FVIII mutations causing hemophilia A (HA), beginning with the Intron 22 Inversion (I22I) defect, which accounts for 45% of all severe HA patients.